OSI Systems Reports Fiscal 2022 Second Quarter Financial Results
OSI Systems reported Q2 revenues of $277 million, with a GAAP EPS of $1.09 and a non-GAAP EPS of $1.28. The company ended the quarter with a backlog of $1.2 billion, a 12% increase from the previous year. While overall revenues remained stable year-over-year, net income decreased slightly from $20 million in Q2 2021 to $19.8 million in Q2 2022. The company has reduced its FY 2022 revenue guidance but increased its EPS guidance due to stronger operating margins, citing ongoing supply chain challenges and COVID-19 impacts.
- Increased FY 2022 non-GAAP EPS guidance from $5.72 - $6.00 to $5.75 - $6.02.
- Q2 backlog rose to $1.2 billion, a 12% increase from the previous year.
- Optoelectronics division reported record revenues and operating income.
- Generated $14.5 million in cash from operations during Q2.
- Q2 net income decreased from $20 million in Q2 2021 to $19.8 million in Q2 2022.
- Reduced FY 2022 revenue guidance from $1.190 billion - $1.225 billion to $1.160 billion - $1.195 billion.
-
Q2 Revenues of
$277 Million -
Q2 Earnings Per Diluted Share
-
GAAP EPS of
$1.09 -
Non-GAAP EPS of
$1.28
-
GAAP EPS of
-
Q2 Ending Backlog of
($1.2 Billion 12% increase fromJune 30, 2021 ) - Company Increases FY 2022 Earnings Guidance and Reduces FY 2022 Revenues Guidance
The Company reported revenues of
For the six months ended
For the three and six months ended
During the second quarter of fiscal 2022, the Company refinanced its credit facility, expanding its borrowing capacity from
Fiscal Year 2022 Outlook
|
Previous Guidance |
Current Guidance |
|
|
|
Revenues |
|
|
|
|
|
Non-GAAP Diluted Earnings Per Share |
|
|
|
|
|
The Company is increasing its non-GAAP diluted earnings per share guidance given an anticipated stronger operating margin. The Company is adjusting its fiscal year 2022 revenues guidance as set forth above primarily as a result of the continued impacts stemming from the COVID pandemic. Actual revenues and non-GAAP diluted earnings per share could vary from this guidance due to factors discussed under “Forward-Looking Statements” or other factors, including uncertainties as to the duration and future scope of the COVID-19 pandemic.
The Company’s fiscal 2022 diluted earnings per share guidance is provided on a non-GAAP basis only. The Company does not provide a reconciliation of guidance for non-GAAP diluted EPS to GAAP diluted EPS (the most directly comparable GAAP measure) on a forward-looking basis because the Company is unable to provide a meaningful or accurate compilation of reconciling items and certain information is not available. This is due to the inherent difficulty and complexity in accurately forecasting the timing and amounts of various items included in the calculation of GAAP diluted EPS but excluded in the calculation of non-GAAP diluted EPS, such as acquisition costs and other non-recurring items that have not yet occurred, are out of the Company’s control, or cannot otherwise reasonably be predicted. For the same reasons, the Company is unable to address the significance of unavailable information which may be material and therefore could result in GAAP diluted EPS, the most directly comparable GAAP financial measure, being materially different from projected non-GAAP diluted EPS.
Presentation of Non-GAAP Financial Measures
This earnings release includes a presentation of non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP operating income (loss) by segment and non-GAAP operating margin, all of which are non-GAAP financial measures. The presentation of these non-GAAP figures for the three and six months ended
Reconciliations of GAAP to non-GAAP financial information are provided in the accompanying tables. The financial results calculated in accordance with GAAP and reconciliations from those financial results should be carefully evaluated.
Conference Call Information
The Company will host a conference call and simultaneous webcast beginning at
About
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements relate to the Company's current expectations, beliefs, and projections concerning matters that are not historical facts. Forward-looking statements are not guarantees of future performance and involve uncertainties, risks, assumptions, and contingencies, many of which are outside the Company's control and which may cause actual results to differ materially from those described in or implied by any forward-looking statement. Forward-looking statements include, but are not limited to, information provided regarding expected revenues, earnings, growth, operational performance and impact of the COVID-19 pandemic in fiscal 2022 and beyond. The Company could be exposed to a variety of negative consequences as a result of delays related to the award of domestic and international contracts; failure to secure the renewal of key customer contracts; delays in customer programs; delays in revenue recognition related to the timing of customer acceptance; changes in domestic and foreign government spending and budgetary, procurement and trade policies adverse to the Company's businesses; global economic uncertainty; impact on the Company’s business related to or resulting from the COVID-19 pandemic such as material delays and cancellations of orders or deliveries thereon, supply chain disruptions, plant closures, or other adverse impacts on the Company’s ability to execute business plans; unfavorable currency exchange rate fluctuations; effect of changes in tax legislation; market acceptance of the Company's new and existing technologies, products, and services; the Company's ability to win new business and convert orders received to sales within the current fiscal year; enforcement actions in respect of any noncompliance with laws and regulations, including export control and environmental regulations and the matters that are the subject of some or all of the Company's investigations and compliance reviews; contract and regulatory compliance matters, and actions which, if brought, could result in judgments, settlements, fines, injunctions, debarment, or penalties; and other risks and uncertainties, including, but not limited to, those detailed herein and from time to time in the Company's
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) |
||||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
|||||||||||||
2020 |
2021 |
2020 |
2021 |
|||||||||||||
Revenues: |
||||||||||||||||
Products |
$ |
208,367 |
|
$ |
205,377 |
|
$ |
391,114 |
|
$ |
412,589 |
|
||||
Services |
|
67,642 |
|
|
71,304 |
|
|
139,803 |
|
|
143,349 |
|
||||
Total revenues |
|
276,009 |
|
|
276,681 |
|
|
|
530,917 |
|
|
|
555,938 |
|
||
Cost of goods sold: |
|
|
|
|
|
|
||||||||||
Products |
|
139,893 |
|
|
139,060 |
|
|
|
264,734 |
|
|
|
281,966 |
|
||
Services |
|
34,035 |
|
|
37,848 |
|
|
|
68,351 |
|
|
|
74,869 |
|
||
Total cost of goods sold |
|
173,928 |
|
|
176,908 |
|
|
|
333,085 |
|
|
|
356,835 |
|
||
Gross profit |
|
102,081 |
|
|
99,773 |
|
|
|
197,832 |
|
|
|
199,103 |
|
||
Operating expenses: |
|
|
|
|
|
|
||||||||||
Selling, general and administrative |
|
56,101 |
|
|
54,879 |
|
|
|
114,718 |
|
|
|
112,202 |
|
||
Research and development |
|
13,784 |
|
|
14,977 |
|
|
|
25,866 |
|
|
|
29,794 |
|
||
Impairment, restructuring and other charges (benefit), net |
|
(162 |
) |
|
831 |
|
|
|
8,197 |
|
|
|
3,341 |
|
||
Total operating expenses |
|
69,723 |
|
|
70,687 |
|
|
|
148,781 |
|
|
|
145,337 |
|
||
Income from operations |
|
32,358 |
|
|
29,086 |
|
|
|
49,051 |
|
|
|
53,766 |
|
||
Interest and other expense, net |
|
(4,233 |
) |
|
(2,217 |
) |
|
|
(8,422 |
) |
|
|
(4,233 |
) |
||
Income before income taxes |
|
28,125 |
|
|
26,869 |
|
|
|
40,629 |
|
|
|
49,533 |
|
||
Provision for income taxes |
|
(8,087 |
) |
|
(7,072 |
) |
|
|
(11,247 |
) |
|
|
(10,684 |
) |
||
Net income | $ |
20,038 |
|
$ |
19,797 |
|
$ |
29,382 |
|
$ |
38,849 |
|
||||
Diluted earnings per share |
$ |
1.10 |
|
$ |
1.09 |
|
|
$ |
1.61 |
|
|
$ |
2.13 |
|
||
Weighted average shares outstanding – diluted |
|
18,196 |
|
|
18,106 |
|
|
|
18,266 |
|
|
|
18,203 |
|
||
UNAUDITED SEGMENT INFORMATION (in thousands) |
||||||||||||||||
|
Three Months Ended
|
|
Six Months Ended
|
|||||||||||||
|
2020 |
|
2021 |
|
2020 |
|
2021 |
|||||||||
Revenues – by Segment: |
|
|
|
|
|
|
|
|||||||||
Security division |
$ |
145,236 |
|
|
$ |
145,918 |
|
|
$ |
280,011 |
|
|
$ |
295,435 |
|
|
Healthcare division |
|
54,895 |
|
|
|
52,425 |
|
|
|
106,398 |
|
|
|
103,013 |
|
|
Optoelectronics and Manufacturing division, including intersegment revenues |
|
87,521 |
|
|
|
91,490 |
|
|
|
167,435 |
|
|
|
183,795 |
|
|
Intersegment eliminations |
|
(11,643 |
) |
|
|
(13,152 |
) |
|
|
(22,927 |
) |
|
|
(26,305 |
) |
|
Total |
$ |
276,009 |
|
|
$ |
276,681 |
|
|
$ |
530,917 |
|
|
$ |
555,938 |
|
|
|
|
|
|
|
|
|
|
|||||||||
Operating income (loss) – by Segment: |
|
|
|
|
|
|
|
|||||||||
Security division |
$ |
19,776 |
|
|
$ |
18,171 |
|
|
$ |
28,682 |
|
|
$ |
39,764 |
|
|
Healthcare division |
|
9,323 |
|
|
|
7,030 |
|
|
|
18,307 |
|
|
|
12,950 |
|
|
Optoelectronics and Manufacturing division |
|
10,414 |
|
|
|
13,382 |
|
|
|
19,154 |
|
|
|
23,165 |
|
|
Corporate |
|
(7,361 |
) |
|
|
(9,663 |
) |
|
|
(16,817 |
) |
|
|
(22,126 |
) |
|
Intersegment eliminations |
|
206 |
|
|
|
166 |
|
|
|
(275 |
) |
|
|
13 |
|
|
Total |
$ |
32,358 |
|
|
$ |
29,086 |
|
|
$ |
49,051 |
|
|
$ |
53,766 |
|
|
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
||||||
|
|
|
|
|||
Assets |
|
|
|
|||
|
|
|
|
|||
Cash and cash equivalents |
$ |
80,613 |
|
$ |
86,332 |
|
Accounts receivable, net |
290,653 |
|
288,037 |
|||
Inventories |
294,208 |
|
334,242 |
|||
Other current assets |
43,930 |
|
61,179 |
|||
Total current assets |
709,404 |
|
769,790 |
|||
Property and equipment, net |
118,004 |
|
116,115 |
|||
|
320,304 |
|
320,319 |
|||
Intangible assets, net |
127,608 |
|
126,643 |
|||
Other non-current assets |
109,047 |
|
110,239 |
|||
Total Assets |
$ |
1,384,367 |
|
$ |
1,443,106 |
|
|
|
|
|
|||
Liabilities and Stockholders' Equity |
|
|
|
|||
|
|
|
|
|||
Bank lines of credit |
$ |
-- |
|
$ |
81,622 |
|
Current portion of long-term debt |
846 |
|
287,247 |
|||
Accounts payable and accrued expenses |
210,077 |
|
200,964 |
|||
Other current liabilities |
133,844 |
|
124,622 |
|||
Total current liabilities |
344,767 |
|
694,455 |
|||
Long-term debt |
276,421 |
|
602 |
|||
Other long-term liabilities |
123,359 |
|
127,901 |
|||
Total liabilities |
744,547 |
|
822,958 |
|||
Total stockholders’ equity |
639,820 |
|
620,148 |
|||
Total Liabilities and Stockholders’ Equity |
$ |
1,384,367 |
|
$ |
1,443,106 |
|
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME AND EARNINGS PER SHARE (in thousands, except earnings per share data) |
||||||||||||||||||||||||||||||||
|
Three Months Ended
|
Six Months Ended
|
||||||||||||||||||||||||||||||
|
2020 |
2021 |
2020 |
2021 |
||||||||||||||||||||||||||||
|
Net income |
EPS |
Net income |
EPS |
Net income |
EPS |
Net income |
EPS |
||||||||||||||||||||||||
GAAP basis |
$ |
20,038 |
|
$ |
1.10 |
|
$ |
19,797 |
|
$ |
1.09 |
|
$ |
29,382 |
|
$ |
1.61 |
|
$ |
38,849 |
|
$ |
2.13 |
|
||||||||
Impairment, restructuring and other charges (benefit), net |
|
(162 |
) |
|
(0.01 |
) |
|
831 |
|
|
0.05 |
|
|
8,197 |
|
|
0.45 |
|
|
3,341 |
|
|
0.18 |
|
||||||||
Amortization of acquired intangible assets |
|
3,704 |
|
|
0.20 |
|
|
3,162 |
|
|
0.18 |
|
|
7,480 |
|
|
0.41 |
|
|
6,360 |
|
|
0.36 |
|
||||||||
Non-cash interest expense |
|
2,260 |
|
|
0.12 |
|
|
57 |
|
|
-- |
|
|
4,486 |
|
|
0.25 |
|
|
125 |
|
|
0.01 |
|
||||||||
Tax benefit of above adjustments |
|
(1,600 |
) |
|
(0.08 |
) |
|
(1,009 |
) |
|
(0.06 |
) |
|
(5,546 |
) |
|
(0.31 |
) |
|
(2,476 |
) |
|
(0.14 |
) |
||||||||
Impact from discrete income tax items |
|
347 |
|
|
0.02 |
|
|
347 |
|
|
0.02 |
|
|
71 |
|
|
-- |
|
|
(1,798 |
) |
|
(0.10 |
) |
||||||||
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Non-GAAP basis |
$ |
24,587 |
|
$ |
1.35 |
|
$ |
23,185 |
|
$ |
1.28 |
|
$ |
44,070 |
|
$ |
2.41 |
|
$ |
44,401 |
|
$ |
2.44 |
|
||||||||
RECONCILIATION OF GAAP TO NON-GAAP
OPERATING INCOME (LOSS) AND OPERATING MARGIN BY SEGMENT (in thousands, except percentages) |
|||||||||||||||||||||||||||||
Three Months Ended |
|||||||||||||||||||||||||||||
|
|
Security Division |
|
Healthcare Division |
|
Optoelectronics and Manufacturing Division |
|
Corporate / Elimination |
|
Total |
|||||||||||||||||||
|
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
|
|
% of Sales |
|||||||||||
GAAP basis – operating income (loss) |
|
$ |
19,776 |
|
13.6 |
% |
|
$ |
9,323 |
|
17.0 |
% |
|
$ |
10,414 |
|
11.9 |
% |
|
$ |
(7,155 |
) |
|
$ |
32,358 |
|
|
11.7 |
% |
Restructuring and other charges (benefit), net |
|
|
269 |
|
0.2 |
% |
|
|
27 |
|
-- |
|
|
|
-- |
|
-- |
|
|
|
(458 |
) |
|
|
(162 |
) |
|
(0.1 |
%) |
Amortization of acquired intangible assets |
|
|
2,732 |
|
1.9 |
% |
|
|
201 |
|
0.4 |
% |
|
|
771 |
|
0.9 |
% |
|
|
- - |
|
|
|
3,704 |
|
|
1.4 |
% |
Non-GAAP basis– operating income (loss) |
|
$ |
22,777 |
|
15.7 |
% |
|
$ |
9,551 |
|
17.4 |
% |
|
$ |
11,185 |
|
12.8 |
% |
|
$ |
(7,613 |
) |
|
$ |
35,900 |
|
|
13.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Three Months Ended |
|||||||||||||||||||||||||||||
|
|
Security Division |
|
Healthcare Division |
|
Optoelectronics and Manufacturing Division |
|
Corporate / Elimination |
|
Total |
|||||||||||||||||||
|
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
|
|
% of Sales |
|||||||||||
GAAP basis – operating income (loss) |
|
$ |
18,171 |
|
12.5 |
% |
|
$ |
7,030 |
|
13.4 |
% |
|
$ |
13,382 |
|
14.6 |
% |
|
$ |
(9,497 |
) |
|
$ |
29,086 |
|
|
10.5 |
% |
Impairment, restructuring and other charges, net |
|
|
353 |
|
0.2 |
|
|
|
- |
|
- |
|
|
|
- |
|
- |
|
|
|
478 |
|
|
|
831 |
|
|
0.3 |
% |
Amortization of acquired intangible assets |
|
|
2,251 |
|
1.5 |
|
|
|
201 |
|
0.4 |
|
|
|
710 |
|
0.8 |
|
|
|
- |
|
|
|
3,162 |
|
|
1.2 |
% |
Non-GAAP basis– operating income (loss) |
|
$ |
20,775 |
|
14.2 |
% |
|
$ |
7,231 |
|
13.8 |
% |
|
$ |
14,092 |
|
15.4 |
% |
|
$ |
(9,019 |
) |
|
$ |
33,079 |
|
|
12.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Six Months Ended |
|||||||||||||||||||||||||||||
|
|
Security Division |
|
Healthcare Division |
|
Optoelectronics and Manufacturing Division |
|
Corporate / Elimination |
|
Total |
|||||||||||||||||||
|
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
|
|
% of Sales |
|||||||||||
GAAP basis – operating income (loss) |
|
$ |
28,682 |
|
10.2 |
% |
|
$ |
18,307 |
|
17.2 |
% |
|
$ |
19,154 |
|
11.4 |
% |
|
$ |
(17,092 |
) |
|
$ |
49,051 |
|
|
9.2 |
% |
Restructuring and other charges (benefit), net |
|
|
8,522 |
|
3.1 |
% |
|
|
27 |
|
-- |
|
|
|
146 |
|
0.1 |
% |
|
|
(498 |
) |
|
|
8,197 |
|
|
1.6 |
% |
Amortization of acquired intangible assets |
|
|
5,545 |
|
2.0 |
% |
|
|
403 |
|
0.4 |
% |
|
|
1,532 |
|
0.9 |
% |
|
|
-- |
|
|
|
7,480 |
|
|
1.4 |
% |
Non-GAAP basis– operating income (loss) |
|
$ |
42,749 |
|
15.3 |
% |
|
$ |
18,737 |
|
17.6 |
% |
|
$ |
20,832 |
|
12.4 |
% |
|
$ |
(17,590 |
) |
|
$ |
64,728 |
|
|
12.2 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||
Six Months Ended |
|||||||||||||||||||||||||||||
|
|
Security Division |
|
Healthcare Division |
|
Optoelectronics and Manufacturing Division |
|
Corporate / Elimination |
|
Total |
|||||||||||||||||||
|
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
% of Sales |
|
|
|
|
|
% of Sales |
|||||||||||
GAAP basis – operating income (loss) |
|
$ |
39,764 |
|
13.5 |
% |
|
$ |
12,950 |
|
12.6 |
% |
|
$ |
23,165 |
|
12.6 |
% |
|
$ |
(22,113 |
) |
|
$ |
53,766 |
|
|
9.7 |
% |
Impairment, restructuring and other charges, net |
|
|
628 |
|
0.2 |
% |
|
|
- |
|
- |
|
|
|
- |
|
- |
|
|
|
2,713 |
|
|
|
3,341 |
|
|
0.6 |
% |
Amortization of acquired intangible assets |
|
|
4,537 |
|
1.5 |
% |
|
|
403 |
|
0.8 |
|
|
|
1,420 |
|
0.8 |
% |
|
|
- |
|
|
|
6,360 |
|
|
1.1 |
% |
Non-GAAP basis– operating income (loss) |
|
$ |
44,929 |
|
15.2 |
% |
|
$ |
13,353 |
|
13.4 |
% |
|
$ |
24,585 |
|
13.4 |
% |
|
$ |
(19,400 |
) |
|
$ |
63,467 |
|
|
11.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20220127005379/en/
Vice President, Business Development
Tel: (310) 349-2237
avashishat@osi-systems.com
Source:
FAQ
What were OSIS revenue figures for Q2 2022?
How did OSIS perform in terms of earnings per share in Q2 2022?
What is the current backlog status for OSIS?
How has OSIS adjusted its revenue guidance for FY 2022?